obamaDesperate for a legacy, Obama spending $215 million on DNA research

Barack Obama has announced he will spend $215 million to collect DNA from 1 million Americans so doctors can learn more about disease.

Obama’s “Precision Medicine Initiative” is the same thing countless universities are already doing with taxpayer dollars. Private biomedical firms are also conducting the research at no cost to the taxpayer.

Knowing a patient’s personal genetic record may help doctors tailor care to the individual, though doctors already know this without spending $215 million in tax money.

Obama claims the initiative will cure cancer and diabetes. The initiative does not study any cure for cancer or diabetes. It simply seeks to find ways to personalize treatment.

Obama frequently compares his initiative to the project that cured polio. That effort was conducted by Jonas Salk under the March of Dimes, a private charity.

$130 million of the $215 million will be spent on the research portion, including DNA collection. Private companies like Ancestry.com, 23andme.com and others will have already collected DNA from over 1.5 million Americans by the end of the year, who paid $99 for the process.

Obama has promised all personal genetic information will be secure. So far this year hackers have stolen 100,000 taxpayer records from the Obama IRS. Hackers have also broken into the Healthcare.gov Obamacare website.

While the effort likely won’t cure any disease, it could let Obama be remembered for something other than wrecking the nation’s health care system.

“Let’s be honest: these initiatives are partly there to make the president look presidential (hoping voters remember Kennedy sending men to the moon and not Nixon’s War on Cancer),” writes Forbes’ Matthew Harper.

While Kennedy raced the Soviets to the moon, Obama seems more focused on trying to defeat the private sector.

According to Harper, many private firms are already conducting this research, “including those of the billionaire Patrick Soon-Shiong’s NantHealth, Craig Venter’s startup Human Longevity, and the biotechnology company Regeneron.”

If successful, it would mark yet another medical breakthrough achieved by the private sector. Obama’s effort to defeat the private sector is led “by NIH chief Francis Collins, who dueled with Venter’s private company during the last human genome race.”

In search of a legacy, and driven by a desire to socialize all sectors of health care, the only supposed cancer Obama is trying to cut out is private sector medicine.